Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
0.0 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
125
Market Cap
3.71M

Momentum Score

…

Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
-
Low
-
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Acusphere Inc (ACUS.US) is an OTC Pink–listed company for which public disclosures about operations, products, and financial condition are sparse, preventing a clear description of its core business. Major long-term growth drivers cannot be identified from available filings, and investors may find the company attractive only if future validated disclosures and credible strategic or financial plans emerge.

The most important risks are very low trading liquidity, regulatory and listing risks associated with Pink-tier securities, potential lack of access to capital and high share-price volatility.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
2.68M
Revenue Per Share
0.57
Gross Profit TTM
-31.77M
Debt / Equity
0.76
ROE
-
Net Debt
-8.09M
ROCE
-462.41%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2008-12-31 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Type yearly yearly yearly yearly yearly
Date 2008-12-31 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Income before tax -67.73M 51.46M 63.20M 46.43M 30.47M
Net income -67.73M -53.73M -61.09M -44.63M -29.96M
Selling general administrative 10.70M 16.17M 14.66M 10.47M 27.30M
Gross profit -31.77M 2.67M 1.78M 3.43M 1.71M
Ebit -42.47M -51.46M -63.20M -46.43M -30.47M
Ebitda - -43.67M -52.91M -42.43M -29.10M
Depreciation and amortization - 7.80M 10.29M 4.01M 1.37M
Operating income -42.47M 52.73M 62.28M 46.18M 30.43M
Other operating expenses - 55.39M 64.06M 49.61M 32.14M
Interest expense 0.00M 2.05M 2.27M 0.55M 0.13M
Income tax expense 0.00M 1.00M -1.19M -1.55M -0.47M
Total revenue 2.68M 2.67M 1.78M 3.43M 1.71M
Total operating expenses 45.16M 55.39M 64.06M 49.61M 32.14M
Cost of revenue 34.45M 39.23M 47.91M 33.92M 3.47M
Total other income expense net -25.26M -1.26M 0.92M 0.26M 0.04M
Net income from continuing ops -67.73M -53.73M -61.09M -44.62M -
Net income applicable to common shares -69.42M -56.01M -63.47M -47.04M -
Breakdown 2008-12-31 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Type yearly yearly yearly yearly yearly
Date 2008-12-31 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Total assets 23.11M 52.02M 94.82M 95.84M 62.00M
Other current assets 1.25M 1.26M 0.84M 1.14M 2.10M
Total liab 51.62M 28.28M 36.37M 38.42M 16.49M
Total stockholder equity -28.50M 23.74M 58.45M 57.42M 45.51M
Deferred long term liab - - 4.67M 2.58M -
Other current liab 13.93M 3.61M 4.14M 7.91M 8.79M
Common stock -28.50M 0.46M 0.38M 0.23M 0.18M
Retained earnings - -334.87M -281.14M -220.05M -175.43M
Other liab 14.44M 3.07M 12.37M 8.14M 0.86M
Other assets 5.41M 1.60M 1.84M 3.55M 1.86M
Cash 16.45M 26.10M 59.75M 51.11M 45.18M
Total current liabilities 13.93M 18.83M 22.32M 21.24M 13.13M
Current deferred revenue - 4.67M 2.67M 3.43M 3.43M
Net debt - -8.09M -37.47M -29.78M -41.61M
Short term debt 23.25M 8.56M 12.90M 6.73M 1.07M
Short long term debt 23.25M 4.93M 12.90M 6.73M -
Short long term debt total - 18.01M 22.28M 21.33M 3.57M
Other stockholder equity - 358.14M 678.45M 555.18M 221.67M
Property plant equipment - 23.05M 32.39M 40.03M 12.87M
Total current assets 17.70M 27.37M 60.59M 52.25M 47.28M
Net tangible assets -28.50M 23.73M 58.44M 57.41M -
Long term debt 23.25M 6.34M 1.68M 9.03M 2.50M
Accounts payable - 1.99M 2.62M 3.18M 4.24M
Accumulated other comprehensive income - - -0.02M -0.36M -0.91M
Preferred stock total equity - 0.01M 0.01M 0.01M -
Non currrent assets other - 1.41M 1.78M 1.75M 1.86M
Non current assets total - 24.65M 34.23M 43.59M 14.73M
Breakdown 2008-12-31 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Type yearly yearly yearly yearly yearly
Date 2008-12-31 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Change to liabilities 0.00M -0.63M 2.26M 4.09M 4.98M
Total cashflows from investing activities - -0.99M -1.22M -32.87M -
Net borrowings - -7.51M -1.36M 12.19M -
Total cash from financing activities - 9.05M 57.95M 69.48M 22.38M
Change to operating activities - -1.05M -2.46M 2.16M -
Net income -67.73M -53.73M -61.09M -44.63M -29.96M
Change in cash - -33.65M 8.64M 5.93M -9.38M
Begin period cash flow 26.10M 59.75M 51.11M 45.18M 54.56M
End period cash flow - 26.10M 59.75M 51.11M 45.18M
Total cash from operating activities - -41.71M -48.09M -30.68M -19.32M
Depreciation - 7.80M 10.29M 4.01M 1.37M
Other cashflows from investing activities - 0.00M -0.13M 0.11M -
Dividends paid - 2.27M 2.38M 2.22M -
Sale purchase of stock - 18.83M 61.69M 17.62M -
Other cashflows from financing activities - -7.51M -1.36M 12.19M 0.00M
Change to netincome - 3.46M 2.92M 3.68M -
Capital expenditures 0.00M 1.00M 1.09M 32.98M 12.18M
Change in working capital - -1.68M -0.21M 6.25M 9.59M
Other non cash items - 5.90M 2.92M 3.68M -0.32M
Free cash flow - -42.70M -49.18M -63.66M -31.50M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MKKGY
Merck KGaA ADR
-0.36
1.11%
32.13 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
-
-%
163.45 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR
0.38
1.77%
21.79 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.
-
-%
43.05 - 10.66 0.01 1.16 2.94 23.11

Profile*

Acusphere Inc

Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.

500 Arsenal Street, Watertown, MA, United States, 02472

617-648-8800

Name Title Year Born
Dr. William I. Ramage D.Phil Chief Devel. Officer 1954
Dr. William I. Ramage D.Phil Chief Development Officer 1954

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…